Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc34927793    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34927793  :  Publisher

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern #MMPMID34927793
  • Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U
  • EMBO Rep 2022[Feb]; 23 (2): e53865 PMID34927793show ga
  • The ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants of concern (VOCs) requires continued development of effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nbs) specific for the receptor-binding domain (RBD) of SARS-CoV-2. Taking advantage of detailed epitope mapping, we generate two biparatopic Nbs (bipNbs) targeting a conserved epitope outside and two different epitopes inside the RBD:ACE2 interface. Both bipNbs bind all currently circulating VOCs with high affinities and are capable to neutralize cellular infection with VOC B.1.351 (Beta) and B.1.617.2 (Delta) in vitro. To assess if the bipNbs NM1267 and NM1268 confer protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice are treated intranasally before infection with a lethal dose of SARS-CoV-2 B.1, B.1.351 (Beta) or B.1.617.2 (Delta). Nb-treated mice show significantly reduced disease progression and increased survival rates. Histopathological analyses further reveal a drastically reduced viral load and inflammatory response in lungs. These data suggest that both bipNbs are broadly active against a variety of emerging SARS-CoV-2 VOCs and represent easily applicable drug candidates.
  • |*COVID-19[MESH]
  • |*Single-Domain Antibodies/genetics[MESH]
  • |Animals[MESH]
  • |Antibodies, Neutralizing[MESH]
  • |Antibodies, Viral[MESH]
  • |Humans[MESH]
  • |Mice[MESH]
  • |Mice, Transgenic[MESH]
  • |Pandemics[MESH]
  • |SARS-CoV-2[MESH]
  • |Spike Glycoprotein, Coronavirus[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    e53865 2.23 2022